Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women

[1]  E. Brankin,et al.  Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study , 2006, International journal of clinical practice.

[2]  S. Silverman,et al.  Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. , 2006, Mayo Clinic proceedings.

[3]  Krista F Huybrechts,et al.  Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. , 2006, Bone.

[4]  B. Ettinger,et al.  Persistence with weekly alendronate therapy among postmenopausal women , 2006, Osteoporosis International.

[5]  J. Cramer,et al.  Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis* , 2005, Current medical research and opinion.

[6]  R. Recker,et al.  Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. , 2005, Mayo Clinic proceedings.

[7]  Rishi Sikka,et al.  Estimating medication persistency using administrative claims data. , 2005, The American journal of managed care.

[8]  C. Christiansen,et al.  Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  G. Fuleihan,et al.  Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. , 2004, Maturitas.

[10]  Jinhai Shi,et al.  Compliance with drug therapies for the treatment and prevention of osteoporosis. , 2004, Maturitas.

[11]  Krista F. Huybrechts,et al.  The impact of compliance with osteoporosis therapy on fracture rates in actual practice , 2004, Osteoporosis International.

[12]  R. Eastell,et al.  The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. , 2004, The Journal of clinical endocrinology and metabolism.

[13]  S. Emani,et al.  Compliance with pharmacologic therapy for osteoporosis , 2003, Osteoporosis International.

[14]  E. Lewiecki,et al.  Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. , 2002, Clinical therapeutics.

[15]  J. Cramer,et al.  A systematic review of the associations between dose regimens and medication compliance. , 2001, Clinical therapeutics.

[16]  P Geusens,et al.  Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. , 2001, The New England journal of medicine.

[17]  H K Genant,et al.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.

[18]  K. Farmer,et al.  Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. , 1999, Clinical therapeutics.

[19]  D. Felsenberg,et al.  Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study , 1999, Osteoporosis International.

[20]  B. Motheral,et al.  The use of claims databases for outcomes research: rationale, challenges, and strategies. , 1997, Clinical therapeutics.

[21]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[22]  P. Delmas,et al.  Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. , 1994, The Journal of clinical endocrinology and metabolism.

[23]  H. Genant,et al.  The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. , 1993, The Journal of clinical endocrinology and metabolism.

[24]  W. Ray,et al.  Identification of fractures from computerized Medicare files. , 1992, Journal of clinical epidemiology.

[25]  C. Cooper,et al.  Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation , 2004, Osteoporosis International.

[26]  H. Rodbard,et al.  American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. , 2003, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[27]  J. Digennaro,et al.  Short-Term Risedronate Treatment in Postmenopausal Women: Effects on Biochemical Markers of Bone Turnover , 2000, Osteoporosis International.

[28]  M. Hooper,et al.  Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis , 2000, Osteoporosis International.

[29]  A V Prochazka,et al.  The assessment of refill compliance using pharmacy records: methods, validity, and applications. , 1997, Journal of clinical epidemiology.